← Eichor
Study identifier: NCT01195558 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Patient Registry of Blind Subjects With Sleep-related Problems

Condition: Sleep-wake Disorder in Blind Individuals  ·  Sponsor: Vanda Pharmaceuticals

PhaseN/A
Planned participants10000
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.

This description comes directly from the study's public registry record.

Talk to the study team

Vanda Pharmaceuticals  ·  (202) 734-3400

Always discuss trial participation with your own doctor first.

Locations (1)

Vanda PharmaceuticalsWashington D.C., District of Columbia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT01195558